Lung Cancer

Full commercial rights to GVAX vaccines reacquired

Published in Cancer Weekly, November 19th, 2002

Cell Genesys, Inc., (NASDAQ:CEGE) announced that it has reacquired full commercial rights to GVAX lung cancer vaccines following the termination of its remaining license agreement with the pharmaceutical division of Japan Tobacco, Inc. (JT).

As a result, Cell Genesys now holds all worldwide commercial rights to its entire portfolio of GVAX cancer vaccine products.

Given the scope of the company's plans for the next clinical trials of GVAX lung cancer vaccine, as well as the anticipated funding from the U.S. National Cancer Institute for one of those trials, Cell Genesys expects the near-term revenue impact from ending the agreement with JT to be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-11-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry